Sanara MedTech (NASDAQ:SMTI) Cut to Buy at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen cut shares of Sanara MedTech (NASDAQ:SMTI – Free Report) from a strong-buy rating to a buy rating in a report released on Saturday morning.

SMTI has been the subject of several other research reports. Zacks Research raised shares of Sanara MedTech from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 10th. HC Wainwright downgraded shares of Sanara MedTech from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $36.00 to $35.00 in a research note on Thursday, July 30th. Freedom Capital raised shares of Sanara MedTech to a “strong-buy” rating in a report on Wednesday, June 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Sanara MedTech in a research report on Friday, July 17th. Finally, Lake Street Capital downgraded shares of Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 price target for the company. in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.00.

View Our Latest Research Report on Sanara MedTech

Sanara MedTech Stock Performance

SMTI opened at $34.00 on Friday. The firm has a market cap of $311.44 million, a P/E ratio of -9.02 and a beta of 1.12. Sanara MedTech has a 52-week low of $16.05 and a 52-week high of $35.95. The company has a debt-to-equity ratio of 6.59, a quick ratio of 2.05 and a current ratio of 2.28. The business’s fifty day moving average is $24.28 and its 200-day moving average is $21.41.

Hedge Funds Weigh In On Sanara MedTech

Several large investors have recently bought and sold shares of SMTI. Vanguard Group Inc. boosted its stake in shares of Sanara MedTech by 3.4% during the third quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after purchasing an additional 6,049 shares in the last quarter. Stonebridge Wealth Management LLC raised its holdings in Sanara MedTech by 1.5% in the 1st quarter. Stonebridge Wealth Management LLC now owns 136,899 shares of the company’s stock valued at $2,352,000 after buying an additional 1,965 shares during the last quarter. Royal Bank of Canada raised its holdings in Sanara MedTech by 11.7% in the 1st quarter. Royal Bank of Canada now owns 131,389 shares of the company’s stock valued at $2,257,000 after buying an additional 13,746 shares during the last quarter. Geode Capital Management LLC raised its holdings in Sanara MedTech by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock valued at $1,846,000 after buying an additional 546 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after buying an additional 42,237 shares during the period. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Company Profile

(Get Free Report)

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.

Featured Articles